16 production sites on 5 continents.
Affiliates or offices in 79 countries.
Products marketed in more than 170 countries.
Approximately 42,100 employees (FTEs December 2017).
19% within research and development
32% in production and production administration
37% in international sales and marketing
12% in administration
Affiliate distribution (FTEs)
Approximately 41% of employees are located in Denmark (17,140 FTEs) and 59% in the rest of the world:
Africa, Asia, Middle East & Oceania: 6,775
Europe (excl. HQ): 4,326
Japan (1,122) & Korea: 1,252
Latin America: 1,866
North America (US 6,079 & Canada 302): 6,381
(includes all Novo Nordisk and NNE employees in the respective locations)
27,992 million Danish kroner
Sales by business segment
Diabetes and obesity care total:
23,143 million Danish kroner
4,849 million Danish kroner
Sales by region
North America Operations:
14,434 million Danish kroner
USA: 13,879 million Danish kroner
13,558 million Danish kroner
Region Europe: 5,418 million Danish kroner
Region AAMEO: 3,068 million Danish kroner
Region China: 2,510 million Danish kroner
Region Japan & Korea: 1,570 million Danish kroner
Region Latin America: 992 million Danish kroner
Novo Nordisk A/S
CVR nr. 24 25 67 90